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Abstract
Major advances in carrier-mediated agents, which include nanoparticles, nanosomes and 
conjugates, have revolutionized drug delivery capabilities over the past decade. While providing 
numerous advantages, such as greater solubility, duration of exposure and delivery to the site of 
action over their small-molecule counterparts, there is substantial variability in systemic clearance 
and distribution, tumor delivery and pharmacologic effects (efficacy and toxicity) of these agents. 
This review provides an overview of factors that affect the pharmacokinetics and 
pharmacodynamics of carrier-mediated agents in preclinical models and patients.
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The number of available nanoparticle (NP)-based drug systems has seen exponential growth 
in the past decade. In 2006 alone, nearly 130 nanotechnology-based products were estimated 
to be undergoing the drug development process worldwide [1]. While the number of agents 
used clinically is still limited, the plethora that are emerging as potential therapeutic agents 
warrants the need for detailed studies of their unique pharmacology and mechanisms of 
action in humans. Caron et al. summarize currently available and late-stage development of 
chemotherapeutic carrier-mediated agents (CMAs) in Supplementary Table 1 (see online at 
www.futuremedicine.com/doi/suppl/10.2217/nnm.14.179) [2]. In this review, we focus on 
factors that affect the pharmacokinetics (PK) and pharmacodynamics (PD) of anticancer 
CMAs in patients, and we hypothesize that many concepts presented within this review will 
be applicable to the vast field of agents to soon enter the clinic.
Pharmacokinetic characterization
The disposition of CMAs is dependent upon the carrier and not the therapeutic entity until 
the drug gets released [3]. The nomenclature used to describe CMA PK includes: 
encapsulated (the drug within or bound to the carrier), released (active drug that gets 
released from the carrier) and sum total (encapsulated drug plus released drug) [4,5]. After 
the drug is released from its carrier, it is pharmacologically active and subject to the same 
routes of metabolism and clearance as the noncarrier form of the drug [5]. In theory, the PK 
disposition of the drug after release from the carrier should be the same as after 
administration of the small molecule or standard formulations. Thus, the pharmacology and 
PK of CMAs are complex and comprehensive. Analytical methods must be performed in 
order to assess the disposition of encapsulated or released forms of the drug in plasma and 
tumor [6]. Considerable interpatient variability exists in the PK/PD of CMAs, and while the 
exact factors are unclear, it is hypothesized that the mononuclear phagocyte system (MPS; 
or reticuloendothelial system) plays a key role [7].
The PK of liposomal encapsulated drug and released drug is very different, and compared 
with conventional small-molecule anti-cancer agents, the PK variability in liposomal 
formulations is often much greater [5,8]. Inter-individual variability in drug exposure, 
represented by area under the concentration versus time curve (AUC), of encapsulated drug 
can be 20- to 100-fold. Factors with the potential to affect CMA PK include CMA-
associated physical characteristics and host-associated characteristics [9]. Perhaps the 
greatest influence on the PK variability of CMA, however, is the MPS. Figure 1 illustrates 
the unique clearance mechanisms associated with CMA as compared with conventional 
small molecules [9,10].
Mononuclear phagocyte system
Once an NP enters the bloodstream, it encounters plasma proteins and immune cells [11]. 
The interaction and subsequent effects of NP therapeutics on the immune system have not 
been fully elucidated, but presently, are generally placed into one of two categories: 
responses to NPs that are specifically modified to stimulate the immune system (e.g., 
vaccine carriers) and undesirable interactions and/or side effects [12]. In this review, we will 
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focus on the latter, which may have profound clinical implications. Here, we describe the 
MPS and the mechanisms of CMA uptake. In the next section, we will describe how MPS 
function affects CMA PK/PD.
NP uptake by immune cells can occur in circulating monocytes, platelets, leukocytes and 
dendritic cells (DCs) of the bloodstream [11,12]. In addition, NPs can be taken up in tissues 
by phagocytes, such as Kupffer cells in the liver, DCs in the lymph nodes, macrophages and 
B cells in the spleen [11]. Figure 2 illustrates the interaction and clearance of CMA with 
these immune cells, collectively termed the MPS. Uptake mechanisms may occur through 
different pathways and are often facilitated by the adsorption of opsonins to the NP surface 
and subsequent phagocytosis [11].
Many NPs have been developed for the purpose of evading rapid clearance from the 
bloodstream and thereby extending systemic circulation time [11]. While this allows for a 
greater probability of NP delivery to a target site, an increase in circulation time results in a 
proportional increase of duration of contact with components of the immune system [11]. 
CMA PK/PD varies between human patients and can be attributed to many variables 
including duration of contact and overall activity of MPS components. In addition, we 
continue to explore the interspecies relationship of MPS function and CMA PK. We have 
seen a positive association between murine models and humans, which will be touched upon 
later in the article [13].
Delivery of CMA in tumor
While conventional drugs encounter numerous obstacles en route to their target, CMAs can 
take advantage of tumor’s leaky vasculature to extravasate into tissue via the enhanced 
permeability and retention effect (EPR) [14,15]. Furthermore, the poor lymphatic drainage 
in tumors leads to accumulation of the CMA for prolonged duration, allowing them to 
release the drug in tumor cells over time. Passive targeting exploits the classic features of 
tumor biology in order to increase exposure of CMA in the tumor.
In theory, EPR has been the primary route of CMA delivery to tumors, but heterogenicity of 
EPR between tumor types and the inability to ensure uniform delivery to all regions of the 
tumor is pressing researchers to dive deeper into EPR fundamentals and the effects of tumor 
vasculature [16–18]. Unevenly distributed blood flow, dense microenvironment and 
variations in vessel permeability play an important role in the distribution and penetration of 
CMAs to tumor [19]. Better and more effective CMAs that exploit EPR are needed while 
also employing methods to address structural hindrances in tumor microenvironment. Jain 
and colleagues, well-known for his efforts in the field of tumor vasculature, explains the 
EPR effect is attributed by physiologic contributions such as vascular pore dimensions, 
vascular structure, surrounding stroma and MPS function [16]. From a preclinical 
perspective, there is a need for tumor models that accurately represent the types of tumors 
seen in patients in order to conduct informative profiling and developmental studies of 
CMAs [16]. It is thought that metastatic, orthotopic and genetically engineered mouse 
models are better options for CMA studies than flank tumor xenografts [16]. However, 
systematic studies of several types of CMAs in each tumor model have not been reported 
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and are desperately needed to advance the field of CMA in the treatment of cancer. 
Clinically, there is a need for diagnostic aids to determine EPR activity in patients and 
predict responders to individual CMAs [16]. Recent approaches to normalize both tumor 
vasculature and physical forces surrounding vessels have been explored [19]. Co-
medications that effect stroma and blood pressure are known to influence EPR effect [16]. 
Mathematical models employed by Jain and colleagues have the potential to reveal an 
optimal vessel perfusion region that maximizes distribution of particular drug or CMA to 
tumor [18].
Active targeting of CMAs may further improve tumor delivery and activity by allowing the 
CMA to bind to specific cells in tumor using surface-attached ligands capable of recognizing 
and binding to cells of interest [20]. Relative to normal cells, tumor cells have certain 
overexpressed surface receptors or antigens that maximize the specificity of binding of 
targeted agents. One such strategy for the tumor-targeted drug delivery is the development 
of immunoliposomes. For example, anti-HER2-targeted liposomal doxorubicin was 
associated with higher efficacy compared with its nontargeted counterpart in a breast cancer 
model [21]. While antibody-mediated targeting has been the method of choice, other 
targeting strategies using nucleic acids, carbohydrates, peptides, aptamers and vitamins are 
also being evaluated [17].
MM-302, currently in early-phase clinical studies, incorporates anti-HER2 scFv-PEG-DSPE 
conjugates to the outer surface of PEGylated liposomal doxorubicin (PLD). In preclinical 
models, MM-302 has shown superior antitumor activity to free doxorubicin and PLD in 
HER2 overexpressing tumors with a pharmacokinetic profile similar to that of PLD. In 
addition, MM-302 expressed a favorable cardiosafety profile compared with free 
doxorubicin [22].
Several preclinical studies support extensive tumor delivery and prolonged exposure of 
PEGylated liposomes in tumors [5]. The development of PEGylated liposomes that contain 
lipid conjugated to PEG was based on a theory that their incorporation into nanosomes 
would evade the immune system and help prolong duration of exposure [9]. This is 
consistent with higher antitumor activity of Doxil in preclinical models compared with 
doxorubicin and with clinical activity in patients with refractory ovarian cancer and Kaposi 
sarcoma [23]. In studies comparing the disposition of PEGylated liposomal CKD-602 (S-
CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts, 
S-CKD602 provided pharmacokinetic advantages in plasma, tumor and tumor extracellular 
fluid (ECF) at 1/30th of the dose [24].
Tumor exposure and antitumor activity of liposomal anticancer agents was found to be 
related to the presence of the MPS in tumors [24]. This was demonstrated in mice bearing 
SKOV-3 human ovarian and A375 human melanoma xenografts [24]. The ratio of S-
CKD602 in tumor to plasma was 1.7-fold higher in mice bearing SKOV-3 compared with 
A375 [24]. The ratio of released CKD-602 to S-CKD602 in tumor was twofold higher in 
mice bearing SKOV-3 compared with A375 [24]. The staining of MPS cells was 4.5-fold 
higher in SKOV-3 compared with A375 (p < 0.0001) [24]. In addition, SKOV-3 was 
fourfold more sensitive to S-CKD602 compared with A375 [24]. The increased tumor 
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delivery and release of CKD-602 from S-CKD602 in SKOV-3 ovarian compared with A375 
melanoma xenografts was consistent with the increased staining of MPS cells in SKOV-3 
suggesting that variability in the MPS may affect the tumor disposition and activity of 
nanosomal anticancer agents [24]. MPS cell staining was utilized to check for consistency of 
results. Limitations such as complete cell specificity do exist. This suggests that tumor type 
may play a role in the PK of CMAs.
In another study using murine colon tumor xenografts, the sum total tumor platinum 
exposure was fourfold higher with PEGylated liposomal cisplatin (SPI-077) compared with 
nonliposomal cisplatin [25]. In spite of fourfold higher exposure associated with SPI-77 
compared with cisplatin, this did not translate into antitumor activity in clinical trials. 
Consistent with that lack of antitumor effects in patients, a subsequent study showed that 
SPI-077 entered tumors but did not release platinum into tumor extracellular fluid and 
formed significantly less platinum (Pt)-DNA adducts than cisplatin [6]. Therefore, as with 
all drugs, it is important that the disposition of both encapsulated and released versions of 
liposomes be evaluated in tumors of patients for successful development of CMA. While 
concentrations of SPI-077 and cisplatin present in tumor ECF do represent an exposure in 
the vicinity of the malignancy, efficacy cannot be assumed based off of this, as cytotoxicity 
is dependent upon the formation of Pt-DNA adducts. An effort to measure direct adduct 
formation would better represent drug efficacy [6]. To address this, microdialysis has been 
used to study the relationship between unbound Pt in tumor ECF and total Pt in tumor 
homogenates, as well as formation of Pt-DNA adducts in a group of female C57BL/6 
bearing B15 melanoma flank tumors [6]. Overall, CMAs have great utility for targeting 
many different tumor types and degree of efficacy is influenced by many variables including 
MPS activity and proper drug action.
Methods to target brain tumors
Treating primary or metastatic tumors within the CNS remains extremely challenging. 
Numerous approaches are being explored to enhance drug delivery and anti-cancer efficacy, 
and the use of NPs and CMAs provides a promising approach to enhance delivery to the 
brain and brain tumors. The mechanism of CMA delivery to the brain is not fully 
understood, but hypotheses such as NP altered distribution and longer blood circulation time 
may allow for enhanced permeation of drugs that have the ability to cross the blood–brain 
barrier (BBB). In addition, brain tumors may also employ similar EPR effect as solid tumors 
in other parts of the body which may be the foundation of enhanced delivery to the CNS 
when compared with small-molecule drug [26–28]. However, the magnitude of the EPR 
effect in intracranial tumors is relatively weak when compared with that of peripheral 
tumors. Explanations for this finding claim smaller pore size for solute passage in these 
tumor types compared with peripheral tumors [29,30]. Systematic studies evaluating these 
mechanisms are needed.
Anders and colleagues utilized an intracranial model of aggressive triple-negative breast 
cancer in athymic mice to evaluate the pharmacologic disposition and activity of PLD 
compared with small-molecule doxorubicin. Treatment with PLD resulted in approximately 
1500-fold higher plasma and 20-fold higher intracranial tumor sum total doxorubicin AUC 
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compared with small-molecule doxorubicin [31]. PLD, measured as sum total doxorubicin, 
was detected at 96 h in plasma and tumor, while small-molecule doxorubicin was 
undetectable after 24 h in plasma and tumor. Median survival of PLD-treated animals was 
32 days ([CI]: 31–38), which was significantly longer than tumor grafts exposed to 
phosphate buffered saline alone (26 days; [CI: 25–28]; p = 0.0012) or mice treated with 
small-molecule doxorubicin (23.5 days; [CI: 18–28]; p = 0.0002) [31]. These data suggest 
that PLD is a treatment option for patients with intracranial metastatic breast cancer.
Researchers are taking advantage of PLD with its inherent longer half-life and better brain 
penetration compared with small-molecule doxorubicin by adding other structural moieties 
that may enhance brain tumor delivery and efficacy. Preclinical studies of PLD with a 
glutathione coating (2B3-101) have also shown promising results in brain cancer models. 
Glutathione, an endogenous tripeptide, is actively transported across the BBB. This inherent 
property is thought to facilitate 2B3-101 in gaining access into the brain. Mouse models 
treated with 2B3-101 have shown greater inhibition of brain tumor growth with significant 
increase in median survival time when compared with PLD [32].
An alternative targeting strategy utilizing spherical nucleic acids (SNAs) NP conjugates has 
shown promise in targeting oncogenes within glioma tumor cells [33]. The ensuing 
dismantling of cancer-promoting signals is believed to cause tumor cell apoptosis. These 
SNAs consist of small interfering RNA (siRNA) coating a gold core. Researchers have 
created a prototypical SNA that has the ability to cross the BBB, where it can enter the 
tumor and exert its effect on a known oncogene (Bcl2L12). In murine models, systemic 
delivery of a particular siRNA-loaded SNA (siL12-2-SNA) rapidly accumulated in 
xenograft brain tumor tissue, where impaired tumor growth and increased survival was 
noted. Figure 3 shows differences in efficacy and survival in mice when treated with 
oncogene-targeted siL12-2-SNA, compared with control scrambled control sequence (siCo)-
SNA [33]. Ultimately, CMAs are of high therapeutic interest for targeting difficult to treat 
organs like the brain due to its characteristic targeted approach of delivering active drug.
Physical characteristics
Particle size
Many groups have demonstrated that tumor uptake of NPs can depend on particle size. In 
one study of liposomes, particles that had a hydrodynamic diameter between 100 and 200 
nm had a fourfold higher rate of uptake in tumors compared with particles less than 50 nm 
or greater than 300 nm [34]. These findings were replicated by Charrois, who found that 
liposomes ranging between 8 and 160 nm resulted in a significantly greater accumulation in 
tumor compared with liposomes greater than 240 nm [35]. It has been shown that particles 
with a hydrodynamic diameter smaller than 50 nm or greater than 300 nm have much shorter 
blood circulation times compared with particles with a hydrodynamic diameter between 100 
and 200 nm, due to increased uptake by the MPS [34]. It is hypothesized that the shorter 
circulation times of particles smaller than 50 nm or greater than 300 nm do not allow the 
particles enough tumor exposure to take advantage of the EPR effect, leading to lower tumor 
accumulation [34]. However, the optimal size of NPs needed to increase blood circulation 
time and delivery to tumors remains unknown and may be influenced by the type of carrier 
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and tumor. As particle size can affect what accumulates in tumor, it can also influence the 
concentrations that can be measured in plasma as well as eventual efficacy and toxicity 
measures.
Particle shape
Particle shape has also been studied to determine the effect on MPS particle recognition. 
Particle-Replication-In-Non-wetting-Templates (PRINT) technology is a soft-lithography 
process used to fabricate monodisperse populations of poly lactic-co-glycolic acid particles 
with high loadings of anticancer drugs [36]. The PRINT particle fabrication technique was 
used to fabricate two different monodisperse shape-specific poly lactic-co-glycolic acid 
particles loaded with the chemotherapeutic docetaxel [36]. The PK of two cylindrical-
shaped particles, one with a diameter of 80 nm and a height of 320 nm (PRINT-
Doc-80×320), and one with a diameter of 200 nm and a height of 200 nm (PRINT-
Doc-200×200), were compared with small-molecule (SM) docetaxel in mice bearing 
SKOV-3 flank xenografts [36]. The concentration versus time profiles for plasma, tumor 
and tissues are shown in Figure 4 [36]. The docetaxel plasma exposure exceeded an increase 
by 20-fold for both particles compared with SM docetaxel [36]. Additionally, the volume of 
distribution of docetaxel in PRINT formulations was approximately 18-fold (PRINT-
Doc-80×320) and approximately 33-fold (PRINT- Doc-200×200) lower than SM docetaxel 
[36]. The prolonged duration of docetaxel in plasma when dosed with PRINT formulations 
subsequently led to increased tumor exposure of docetaxel from 0 to 168 h (~53% higher 
than SM docetaxel for PRINT-Doc-80×320 and ~76% higher than SM docetaxel for 
PRINT-Doc-200×200 particles) [36]. PRINT-Doc-80×320 had lower exposures in the 
organs of the MPS compared with PRINT-Doc-200×200 [36]. Thus, particles shaped to 
have a large aspect ratio may be preferred to decrease clearance by organs of the MPS [36].
Surface modification
In an attempt to minimize opsonization and the subsequent rate of MPS uptake, the most 
commonly used strategy is to conjugate PEG onto the surface [38]. Sadzuka and colleagues 
conducted a PK study using irinotecan (CPT-11) loaded into bare liposomes or PEGylated 
liposomes [38]. They found that the overall exposure in plasma of CPT-11 contained within 
a PEGylated liposome was sixfold higher than that of non-PEGylated liposomes [38].
Surface charge
Drummond and colleagues have studied the effects of surface charge on particle clearance 
and found that uncharged liposomes have a lower clearance than either positively or 
negatively charged liposomes [39]. This is believed to be due to reduced opsonization on the 
uncharged liposomal surface, which leads to less MPS uptake [40]. Levchenko et al. 
conducted a study in which they prepared liposomes of 200 nm in size with different charges 
and studied tissue distribution over time [41]. They found that the rate of clearance from 
blood was significantly higher for negatively charged particles versus uncharged particles 
[41]. Additionally, the negative particles had a higher rate of MPS uptake in the liver 
compared with the uncharged particles, indicating that phagocytic cells resident to the liver 
preferentially take up negatively charged particles and increase the rate of clearance of 
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particles from blood [41]. The most common surface modification, PEGylation, comes in to 
play here, as Levchenko has shown that PEGylation can shield the negative charge on 
liposomes, leading to a significantly reduced rate of liver uptake and prolonged blood 
circulation [41].
Particle dose
Chu et al. studied the effects of particle dose on particle clearance [42]. Docetaxel-loaded 
PRINT NPs with identical size, shape and surface chemistry, but with variable docetaxel 
loading were created [42]. The two different formulations of NPs had 9% (9%-NP) and 20% 
(20%-NP) docetaxel drug loading [42]. Both formulations were administered at identical 
docetaxel doses of 10 mg/kg that resulted in a total NP dose of 109 mg/kg in the 9%-NP 
group compared with only 50 mg/kg in the 20%-NP group [42]. The 9%-NP formulation, 
which is associated with administration of a higher number of NPs, was found to have a 
superior pharmacokinetic profile and enhanced efficacy when compared with that of the 
20%-NPs [42]. Figure 5 shows the pharmacokinetic profiles of the two formulations in 
various tissues [42]. The 9%-NPs increased tumor docetaxel exposure and reduced liver, 
spleen and lung exposure when compared with that of the 20%-NPs [42]. Chu et al. theorize 
that the higher particle dose associated with the 9%-NP formulation may have saturated the 
MPS of the liver and spleen resulting in reduced docetaxel accumulation at those sites 
accounting for the increased tumor docetaxel exposure relative to the 20%-NP group [42]. 
While Chu et al. did not present any data on the MPS function or activity, there are ongoing 
studies to investigate the effect of particle dose on the MPS.
The effect of MPS mediators on NP PK
A Phase I study looked at the relationship between the disposition of the CMA S-CKD602 
(PEGylated liposomal CKD-602, a camptothecin analogue) and changes in monocytes and 
absolute neutrophil count (ANC) [43]. The control of this study was changes in monocytes 
and ANC after patients with refractory solid tumors received nonliposomal CKD-602 [43]. 
The percent decrease in ANC and monocytes from baseline to nadir from the blood of all 
patients administered S-CKD602 on cycle 1 was measured. The mean ± standard deviation
% decrease in ANC and monocytes at the nadir was 42 ± 30 and 58 ± 34%, respectively (p = 
0.001). The ratio of percent decrease in monocytes to ANC at the nadir was 2.1 ± 2.0. The 
percent decrease in ANC and monocytes at the nadir in the blood of patients was also 
assessed after administration of nonliposomal CKD-602. After administration, the percent 
decrease in ANC and monocytes were 86 ± 11 and 87 ± 12%, respectively (p > 0.05). The 
ratio of percent decrease in monocytes to ANC was 1.0 ± 0.2. The results suggest that 
monocytes are more sensitive to S-CKD602 compared with neutrophils. The increased 
sensitivity also appears to be related to the liposomal formulation and not the released drug 
from the liposome or the small-molecule formulation.
Some of the significant variability in the pharmacokinetic dispositions of CMA versus small 
molecules was found to be related to linear and nonlinear clearance of S-CKD602 in patients 
[44]. In the previously mentioned study, despite being treated with the same dose of 1.7 
mg/m2, some patients were found to have linear clearance, while the majority portrayed 
nonlinear clearance [44]. Those with linear clearance had a plasma concentration versus 
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time profile of CKD-602 with a distribution phase and an elimination phase [44]. For 
patients with nonlinear clearance, the plasma concentration versus time profile of CKD-602 
yielded little change from 0 to 24 h [44]. The incidence of linear or nonlinear clearance was 
found to be associated with the dose of S-CKD602 administered [44]. At doses from 0.1 to 
1.1 mg/m2, the S-CKD602 sum total and encapsulated CKD-602 plasma concentrations 
were best described using a model with linear clearance in all the patients (n = 33) [44]. At 
doses of 1.7–2.5 mg/m2, the S-CKD602 sum total and encapsulated CKD-602 plasma 
concentrations were best described using a model with linear (n = 2) and nonlinear (n = 10) 
clearances [44]. The observation of nonlinear PK at higher doses of CMA coincides with the 
hypothesis of MPS uptake in particle clearance and its subsequent saturation. However, 
there was significant interpatient variability in clearance with patients exhibiting linear and 
nonlinear clearance at the same dose.
The Pheno–GLO–high-throughput screening platform (HTSP) is an ex vivo flow cytometry-
based system, used to measure the clearance of NPs by the MPS and bidirectional 
interaction between the MPS and NPs and conjugates [16]. Monocyte (MO) and DC 
function, as assessed by phagocytosis and oxidative burst can predict the PK of PEGylated 
liposomal NPs in several species as well as in patients [13]. Caron et al. measured MO/DC 
phagocytosis and reactive oxygen species production in mice, rats, dogs and patients with 
refractory solid tumors that had been administered a PEGylated liposomal drug formulations 
[13]. Preclinical pharmacokinetic studies of PLD, CKD-602 (S-CKD602) and cisplatin 
(SPI-077) were performed at the maximum tolerated dose [13]. Monocyte/DC function was 
also evaluated in patients with recurrent epithelial ovarian cancer (EOC) administered PLD 
[13]. Figure 6 shows that across species, a positive association was observed between 
monocyte/DC function and clearance of all three PEGylated liposomes. In patients with 
EOC, associations also were observed between PLD clearance and phagocytosis (coefficient 
of determination [R2] = 0.43, p = 0.04) and reactive oxygen species production (R2 = 0.61, p 
= 0.008) in blood monocytes/DCs (Figure 7) [13]. These findings suggest that probes of 
MPS function may help predict PEGylated liposome clearance across species, PLD 
clearance in patients with EOC and perhaps utilized to find the correct dose of PLD and 
other CMAs in the future [13].
Age
Pharmacokinetic studies of Doxil administered in three Phase I and Phase II studies in 
patients with solid tumors and in patients with AIDS-related Kaposi’s sarcoma were 
performed. The mean ± standard deviation clearance of sum total Doxil in patients aged <60 
and ≥60 years old were 54.6 ± 28.5 and 23.3 ± 10.8 ml/h/m2, respectively (p < 0.0001) [45]. 
A more recent study focusing on the effect of age on doxorubicin PK and toxicity after 
administration of PLD was published earlier this year [46]. A total of 35 patients (≥70 years 
old) were enrolled in the study. The mean t1/2 of the first three cycles of PLD in patients 
aged >77 versus ≤77 years old was 99 h versus 72 h (p = 0.02). A more profound 42% 
increase in mean t1/2 was seen when comparing octogenarians to patients in their 70s (p = 
0.005) [46].
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Age-related effects on PD of CMAs have also been reported. The relationship between 
neutropenia and monocytopenia after administration of S-CKD602 was tested by evaluating 
the percent decrease and rate of decrease of ANC and monocytes in patients aged <60 and 
≥60 years of age [43]. Based on overall exposure to encapsulated S-CKD602, it appears that 
there is a greater reduction in monocytes at the nadir in patients aged <60 years of age 
versus ≥60 years of age [43]. This study concluded that monocytes are more sensitive than 
neutrophils to S-CKD602, increased sensitivity is related to the encapsulated liposomal 
formulation of CKD-602 and that age impacts this interaction [43]. This is consistent with 
the age-related effects on the clearance (CL) of PEGylated liposomes.
Age has also been reported to be associated with the toxicity and efficacy of CMA. Figure 8 
from Gusella reports the relationship between age, PLD half-life and palmar-plantar 
erythrodysesthesia (PPE), a hallmark side effect of PLD. Both increasing age and PLD 
plasma half-life correlated with PPE severity [46]. In a multicenter Phase II trial of elderly 
patients (n = 60) with metastatic breast cancer who were treated with Doxil, severe 
nonhematological toxicities were correlated to patient aged >80 years old [47]. In terms of 
efficacy, an increase in age was found to be inversely proportional with progression-free 
survival; however, no correlation between age and overall survival was found [47]. 
Alterations in the PK and PD of CMA may involve age-related decline in immune system 
functioning, specifically the association of aging to the function of monocytes [48]. In 
theory, there is a loss of MPS activity or function in elderly patients which decreases the 
clearance of CMA by MPS and leads to increased drug exposures and toxicity in elderly 
patients.
Gender
Gender was also found to be one of the many factors contributing the PK/PD variability of 
CMAs. The effect of gender on clearance of Doxil (n = 70), IHL-305 (n = 39) and S-
CKD602 (n = 45) was evaluated in PK studies conducted as part of Phase I and Phase II 
studies [49]. Female patients had a 2.4-fold lower overall clearance of Doxil (p < 0.001), a 
1.4-fold lower overall clearance of IHL-305, and a 1.3-fold lower overall clearance of S-
CKD602 compared with male patients [49]. In addition, an evaluation of the plasma PK 
disposition of TLI (liposomal topotecan) and S-CKD602 in male and female rats found the 
clearance of TLI and S-CKD602 to be 1.2-fold and 1.4-fold (p = 0.009) lower in female rats 
compared with male rats, respectively [50]. The basis for the differences in the PK and PD 
of CMA associated with gender is unclear with some ideas suggesting differences may be 
attributed to sex hormones on immune cell function [49].
Tissue & organ effects
Body habitus
Defined as the physical characteristics of an individual leading to a body type of 
underweight, normal weight or overweight, body habitus has been suggested to play an 
important role in PK of drugs cleared by the MPS [44,45]. Common terms used to describe 
an individual’s body habitus include BMI and body surface area (BSA).
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Pharmacokinetic studies of Doxil were conducted as part of three Phase I and Phase II 
studies in patients with solid tumors (34 patients) and in patients with AIDS-related 
Kaposi’s sarcoma (36 patients) [45]. BSA and BMI were evaluated as potential factors that 
affect the clearance of Doxil [45]. The linear regression coefficient between BSA and Doxil 
clearance on cycle 1 was R2 = 0.25. BSA contributed to a relative reduction in variability of 
clearance by 8.6% [45]. There was no significant relationship found between Doxil 
clearance on cycle 1 and body composition as measured by actual body weight/ideal body 
weight (ABW/IBW) or BMI (R2 = 0.22 and 0.13, respectively) [45]. However, it was 
reported that patients with a lean body composition (ABW/IBW <1.35) had a higher plasma 
exposure of S-CKD602 as compared with patients with an ABW/IBW ≥ 1.35 (p = 0.02), 
perhaps due to a smaller volume of distribution [44]. While there was no relationship found 
between body composition and Doxil clearance in this study, this could be due to a lower 
number of patients enrolled [45]. Additional data collection through CMA clinical 
pharmacology studies is warranted in order to further explore the potential relationship 
between body composition and NP clearance.
Presence of liver tumors
In a Phase I pharmacokinetic study evaluating encapsulated and released CKD-602, 45 
patients were enrolled, of which 26 individuals had tumor(s) of all types in their liver [51]. 
Linear and nonlinear pharmacokinetic models were constructed for encapsulated CKD-602, 
and it was determined that liver tumor was a significant covariate for maximum velocity. 
Including liver tumor as a covariate in the model decreased the variation in Vmax by 29%, 
meaning that liver tumors (primary or metastases) were outliers from the general population 
and influenced CMA PK [51]. The interpatient variability in S-CKD602 pharmacokinetic 
disposition could possibly be explained by the presence of metastatic liver tumors, as the 
Vmax of patients with these tumors is 1.5-fold higher than those patients without liver tumors 
[51]. These data suggest that patients with liver tumor may have 35% lower plasma 
exposure of encapsulated CKD-602, leaving them at risk for having a lower response 
potential. This finding is interesting, as historically, most studies show a decrease in 
clearance of small-molecule drugs when patients have tumors in the liver [52,53].
Drug–drug interactions
Drug–drug interactions have been reported to influence the PK and PD of CMAs. In a drug 
interaction study, the PK of Doxil when given as a single agent and in combination with a 
taxane, either paclitaxel (n = 10) or docetaxel (n = 9), was evaluated. Both paclitaxel and 
docetaxel increased the Doxil AUC (p = 0.002 and 0.039, respectively) and decreased the 
clearance of Doxil (p = 0.013 and 0.16, respectively). Administering paclitaxel produced a 
more significant increase in systemic exposure of Doxil than coadministration with 
docetaxel. These findings may explain a high incidence of toxicity observed at relatively 
low doses of Doxil when coadministered with paclitaxel compared with docetaxel [54]. In 
addition, a Phase I study of patients with solid tumors (n = 26) showed that treatment with 
cisplatin followed by Doxil increased the clearance of Doxil compared with patients 
receiving single-agent Doxil. A possible mechanism for this accelerated clearance of Doxil 
is transient macrophage activation induced by cisplatin [55].
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In a Phase I study of factors influencing the inter-patient variability in the pharmacokinetic 
disposition of S-CKD602, the effect of prior chemotherapy on the pharmacokinetic 
disposition of S-CKD602 was evaluated [44]. Patients with advanced malignancies received 
S-CKD602 intravenously (iv.) every 3 weeks. Patients who received prior therapy with 
Doxil (n = 5) had a 2.2-fold higher exposure of sum total AUC/dose S-CKD602 compared 
with patients who did not receive prior Doxil (n = 39; p = 0.045) [44]. In addition, the 
encapsulated AUC/dose of S-CKD602 in patients previously treated with Doxil (n = 5) was 
1.8-fold higher compared with patients who did not receive Doxil (n = 34; p = 0.11). 
However, prior Doxil therapy did not alter the disposition of released CKD-602 [44]. There 
was no relationship found between the disposition of S-CKD602 and the number of PLD 
cycles or the time interval between stopping PLD and starting S-CKD602 [44]. It is unclear, 
if changes in S-CKD602 PK were related to Doxil or patient-related factors as all patients 
that received Doxil were patients with refractory ovarian cancer already exposed to 
chemotherapy.
Bevacizumab is a recombinant humanized mono-clonal VEGF-A antibody that inhibits the 
binding of human VEGF-A to its receptors. Combination treatment of locally recurrent or 
metastatic breast cancer patients (n = 39) with bevacizumab at 10 mg/kg iv. and Doxil at 20 
mg/m2 iv. every 2 weeks resulted in the premature discontinuation of a single-arm Phase II 
trial due to higher than anticipated toxicity [56]. The most significant toxicity noted was 
grade 3 PPE that occurred in an unusually high proportion of patients (41%), suggesting an 
additive toxic effect of combination bevacizumab and Doxil treatment [56]. Possible 
suggested mechanisms of this synergistic toxicity include: direct pharmacological 
interaction between Doxil and bevacizumab; effects of bevacizumab on the vasculature of 
soles, palms and possibly the oral mucosa, resulting in increased accumulation of Doxil in 
these areas; and bevacizumab impairing wound healing of dermal and mucosal injuries [56].
Prior treatment
In addition to the high interpatient variability in the PK of NPs, there may also be high 
intrapatient variability in PK of NPs. Gabizon and colleagues reported that the clearance of 
sum total PLD decreased by approximately 25–50% from cycle 1 to 3 in patients with 
ovarian cancer (Figure 9) [57]. La-Beck and colleagues reported that this reduction in 
clearance of Doxil from cycle 1 to 3 was associated with a reduction in precycle monocyte 
count. These studies suggest that there is a reduction in the clearance of liposomes over time 
that is associated with a reduction in MPS function. Thus, dose reductions may be needed in 
subsequent cycles to minimize the risk of toxicity [57]. However, how the reductions in the 
dose of PLD should be performed in each patient is unclear due to high inter- and intra-
patient variability in changes in MPS function. By phenotypically probing patient MPS 
function prior to administering each cycle of PLD is of interest to guide patient-specific 
dosing [13]. Studies are ongoing to evaluate the use of phenotypic probes of MPS as a 
method to individualize the dose of PLD.
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There are many properties that make CMAs unique from the active small-molecule drug that 
is contained within the nanocarrier. These differences lead to significant variability in the 
PK and PD of CMAs. It has been shown that physical properties, the MPS, presence of 
tumors in the liver, EPR effect, drug–drug interactions, age, gender, body habitus and prior 
treatment all contribute in varying degrees to the pharmacokinetic disposition and 
pharmacodynamic endpoints of CMAs in patients.
Future perspective
Due to the unique and highly variable clearance mechanisms of CMAs, it is important to 
create, validate and utilize assays and models that represent EPR effect and MPS function, 
and use them to evaluate factors that alter PK/PD of CMAs during all phases of 
development. Patient factors that affect MPS function and NP PK/PD variability include 
age, gender and body habitus among others. However, these factors do not account for all of 
the PK/PD variability and thus the development of phenotypic probes of the MPS that 
account for all encompassing factors may be a more appropriate approach to predicting the 
PK/PD of NPs in animal models and patients (Figure 10). These probes could also be used 
to individualize the dose of NPs throughout therapy, as there is high inter- and intrapatient 
variability in MPS function and NP PK. Studies in animal models and patients using 
phenotypic probes of MPS function to predict the clearance of PEGylated liposomal agents 
support this plan. Additional areas of research that can aid in our understanding of how these 
agents are handled and how we may predict their actions in patients include: 
pharmacogenomics, more sensitive and accurate analytical PK methods and identification of 
the optimal preclinical models.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Currently hundreds of nanoparticle (NP)-based drug products are undergoing 
development.
• Clinically available carrier-mediated agents (CMAs) are still limited but 
expected to grow greatly in the near future.
Pharmacokinetic characterization
• The kinetics of CMAs are dependent upon the carrier until the parent drug is 
released.
• Analytical studies must be performed to assess the disposition of CMAs.
Mononuclear phagocyte system
• NPs can be taken up by cells of the mononuclear phagocyte system (MPS; 
Kupffer cells in the liver, dendritic cells in the lymph nodes, macrophages and B 
cells in the spleen).
• Variations within the MPS greatly influence the pharmacokinetics and 
pharmacodynamics of a CMA.
Delivery of CMA in tumor
• CMAs have the ability to extravasate into tissue with help of tumor’s leaky 
vasculature as a result of the enhanced permeability and retention effect.
• New therapeutics are utilizing NPs as delivery systems in both preclinical and 
early phase studies in hard to target areas like the brain.
Physical characteristics
• Particle size and shape:
– Particles between 100 and 200 nm have been most efficient for CMA 
uptake in tumor;
– Particle-Replication-In-Non-wetting-Templates (PRINT) technology can 
easily alter particle shape.
• Surface modification and charge:
– Conjugation of PEG to the surface of NPs increases circulation time and 
encapsulated drug plasma area under the concentration versus time curve;
– Uncharged particles have less MPS uptake and longer circulation time.
• Number of NPs administered:
– Greater number of particles per dose increases the plasma and tumor drug 
exposure.
Monocytes & the MPS
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• There is a high degree of interpatient variability with regards to the clearance of 
NPs:
– Both linear and nonlinear clearances (CLs) of NPs are seen in the clinic;
– Nonlinear CL may be due to saturation of the MPS.
• There is an apparent relationship between NP CL and age, gender, body habitus, 
presence of liver disease, drug–drug interactions and prior treatment.
• Monocyte and dendritic cells function can predict the pharmacokinetics of 
PEGylated liposomal NPs in mice, rats and dogs.
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Figure 1. Metabolism and elimination pathway for small molecule and carrier mediated agents
Small-molecule anticancer agents undergo a standard route of metabolism and elimination, 
including enterohepatic recycling and removal through the kidney. Carrier-mediated agents, 
however, which are engulfed by phagocytes, are contained primarily in compartments such 
as the spleen, liver and peripheral blood mononuclear cells.
IV: Intravenous administration; PBMC: Peripheral blood mononuclear cell; PO: Oral 
administration.
Reproduced with permission from [2].
For color figures, see online at www.futuremedicine.com/doi/full/10.2217/NNM.14.179
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Figure 2. Clearance of nanoparticles and carrier-mediated agents via the mononuclear 
phagocyte system
When nonstabilized liposomal agents were first tested, they were found to only minimally 
increase the circulation time of the small-molecule agent encapsulated within the carrier 
(rapid clearance). However, stabilization with PEG has helped to reduce uptake and CL of 
CMA by MPS (slower clearance). While the clearance of PEGylated liposomes are slower 
than non-PEGylated liposomes, both are phagocytized by peripheral blood mononuclear 
cells, phagocytes of the liver and spleen. Greater tumor exposure is seen after administration 
of PEGylated liposomes, which in part due to the EPR effect and possibly, the MPS in 
tumors.
CL: Clearance; CMA: Carrier-mediated agent; EPR: Enhanced permeability and retention; 
MPS: Mononuclear phagocyte system.
Adapted with permission from [2].
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Figure 3. Intratumoral apoptosis in mice injected with siL12-2-SNA
(A) The amount of aCasp-3 and terminal deoxynucleotidyl TUNEL. Data points are the 
number of stained cells per field. p-values were calculated with two-tailed Student’s t-test. 
(B) Kaplan–Meier survival curves of mice with TNS-derived xenografts treated with 
siL12-2-SNA (n = 6) or siCo-SNA (n = 7). p-value was calculated with the Mantel–Cox test.
aCasp-3: Activated caspase-3; HPF: High-power field; siCo: Scrambled control sequence; 
siL12-2-SNA: siRNA-loaded SNA; SNA: Spherical nucleic acid; TNS: Tumor neurosphere; 
TUNEL: Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick 
end labeling.
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Adapted with permission from [32].
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Figure 4. Plasma and tumor doectaxel vs time curves in mice bearing SKOV3 ovarian flank 
xenografts after administration of three different docetaxel formulations
(A) Tumor (0–168 h), (B) tumor (0–24 h), (C) plasma, (D) lung, (E) spleen and (F) liver. 
Doc concentration values for each mouse are represented in the key. The lines are connected 
by the mean value for each time point.
Reproduced with permission from [37].
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Figure 5. Plasma and tumor doectaxel vs time curves in mice after administration of two 
different shaped nanoparticle docetaxel formulations
Pharmacokinetic profiles of (A) plasma, (B) tumor, (C) liver, (D) spleen and (E) lung. (F) In 
vitro release kinetics of 9%-NP (●) and 20%-NP (■). Each replicate is shown and the lines 
are connected by the mean of three replicates.
Reproduced with permission from [41].
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Figure 6. Relationship between phagocytosis in monocytes/dendritic cells from blood and 
clearance of PEGylated liposomal agents in mice, rats, dogs and patients
The mean values for three species are represented by individual symbols, with diamonds as 
PLD, squares as S-CKD602 and triangles as SPI-077. The species data are in vertical 
columns from left to right: rats, mice, dogs and patients. The best fit line for each group is 
represented by the solid lines. Across species, a positive association was observed between 
cell function and CL of PEGylated liposomes.
CL: Clearance; MFI: Mean fluorescent intensity; MPS: Mononuclear phagocyte system; PK: 
Pharmacokinetics; PLD: PEGylated liposomal doxorubicin; R2: Coefficient of 
determination.
Adapted with permission from [44].
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Figure 7. Relationship between monocytes/dendritic cells function and encapsulated doxorubicin 
clearance in patients presented in a linear regression model
Measuring phagocytosis and production of ROS of MO/dendritic cell from patient blood 
samples at baseline (prior to the start of chemotherapy) was used as a phenotypic probe of 
MPS function and encapsulated doxorubicin CL. Each diamond represents an individual 
patient, and the solid line is the regression line. (A) Phagocytic activity (MFI) is 
significantly correlated with CL of encapsulated doxorubicin in ten patients receiving PLD 
alone or PLD + carboplatin (R2 = 0.43, p = 0.04). (B) Production of ROS: MFI is 
significantly correlated with CL of encapsulated doxorubicin in ten patients receiving PLD 
alone or PLD + carboplatin (R2 = 0.61, p = 0.008). (C) Phagocytic activity: MFI is 
significantly correlated with CL of encapsulated doxorubicin in six patients receiving PLD 
alone (R2 = 0.57, p = 0.03). (D) Production of ROS: MFI is significantly correlated with CL 
of encapsulated doxorubicin in six patients receiving PLD alone (R2 = 0.61, p = 0.001).
CL: Clearance; MFI: Mean fluorescent intensity; MO: Monocyte; MPS: Mononuclear 
phagocyte system; PLD: PEGylated liposomal doxorubicin; R2: Coefficient of 
determination; ROS: Reactive oxygen species.
Reproduced with permission from [44].
Petschauer et al. Page 26













Figure 8. The relationship between hand foot syndrome and PLD pharmacokinetics or age in 
patients receiving PLD treatment
HFS (also called palmar-plantar erythrodysesthesia) association with PLD T1/2 (A) and age 
(B). Longer PLD T1/2 and advanced age resulted in an overall greater severity PPE grade.
ANOVA: Analysis of variance; HFS: Hand foot syndrome; PLD: PEGylated liposomal 
doxorubicin; PPE: Palmar-plantar erythrodysesthesia.
Reproduced with permission from [46].
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Figure 9. Clearance of PEGylated liposomal doxorubicin after chemotherapy cycle in human 
subjects
Bars represent mean values and SEM of clearance of PLD by dose and cycle. p values 
shown were calculated by repeated measures analysis of variance.
CL: Clearance; n.s: Not significant; PLD: PEGylated liposomal doxorubicin; SEM: Standard 
error of the mean.
Adapted with permission from [57].
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Figure 10. Summary of the process to use a phenotypic probe of mononuclear phagocyte system 
function in blood to measure mononuclear phagocyte system function in patients, which would 
predict nanoparticle pharmacokinetics, efficacy and toxicity
his type of probe could be used as a test that could retrospectively be used to explain patients 
with highly variable PK and PD. This type of probe could also be used as a method to 
individualize the dose of nanoparticles as needed.
MPS: Mononuclear phagocyte system; PD: Pharmacodynamics; PK: Pharmacokinetics; 
PPE: Palmar-plantar erythrodysesthesia.
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